“We had that question before, when we only had Enhertu and [Trodelvy]. Now we have three drugs.” When a patient stops responding to one ADC, it’s not always clear if they developed ...

Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ...

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Enhertu against Roche's rival Kadcyla when they reported top-line results ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

Seagen claims Enhertu (trastuzumab deruxtecan) – an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds ...

The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

Enhertu is a HER2-directed antibody-drug conjugate (ADC). Enhertu consists of a HER2 monoclonal antibody linked to multiple topoisomerase 1 inhibitor payloads, including the exatecan derivative DXd, ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

Antibody-drug conjugates (ADCs) are new drugs that combine a monoclonal antibody with a chemotherapy drug. They can specifically target cancer cells to deliver potent chemotherapy drugs.